Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THOR-707-101
2023-508422-95-00Phase 2Completed
- Sponsor
- Synthorx
- Start
- Feb 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 2, open-label trial of pegenzileukin in Nonhematologic neoplasms, cancer, melanoma and 2 more (8 cohorts), sponsored by Synthorx. Primary endpoints: Rate of dose-limiting toxicities (DLTs) - Cohorts A, B, C, and D, Rate of dose-limiting toxicities (DLTs) - Cohort G and 6 more. Started Feb 2024; status: completed.
02
Drugs
pegenzileukin
03
Conditions
Nonhematologic neoplasmscancermelanomacolon cancermetastasis
Beyond the preview
Go deeper on 2023-508422-95-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508422-95-00.